OncoTherics wins Innovate UK Global Feasibility Study Award

OncoTherics wins Innovate UK Global Feasibility Study Award. Project Title: Exploiting Tumour Hypoxia in Precision Medicine:  Advancing Novel Prodrug Therapies for Pancreatic Cancer with PMCC, a World-leading Canadian Cancer Centre.  As part of the award, OncoTherics will work with Alan Boyd Consultancy to explore a regulatory strategy for its novel hypoxia activated pro-drugs.

OCT1002 shows promising results in prostate cancer research

Researchers at Ulster University have just published the latest results of a three-year study looking at OCT1002 in combination with hormone therapy in prostate cancer.

The research programme was supported by Prostate Cancer UK through a £213,000 grant from the Movember Foundation and the latest results have been published in the Journal of Clinical Cancer Research
CLICK HERE to link to the paper.

CLICK HERE to hear Dr Declan McKenna speaking on ITV news about the exciting results.

OncoTherics VOOM's awareness for Pancreatic Cancer!

Over 400 people from around the world have voted for OncoTherics in the VOOM 2016 challenge!

The VOOM 2016 challenge invites small and start-up businesses to canvass votes to qualify for a chance to pitch to Richard Branson.

OncoTherics has used the competition to raise awareness of Pancreatic Cancer and the lack of investment in new therapeutics that can make a difference to overall survival and quality of life.

More thank 10,000 businesses have entered the competition and at the time of writing, OncoTherics  is ranked at number 106 in the Grow category!!

The OncoTherics Team would like to say a huge THANK YOU to all who have voted - your vote has helped raise awareness about Pancreatic Cancer and the real challenges that this disease poses.

Dr Thomas Morris joins OncoTherics as Chief Medical Officer

OncoTherics is delighted to announce the appointment of Dr Thomas Morris as the company's new Director and Chief Medical Officer.

Dr Morris has worked in drug development for over 20 years with much of this time specialising in oncology. He joins OncoTherics after a long and successful career at AstraZeneca where he has held a number of senior global R&D roles. Most recently these include Senior Medical Director, Executive Director Clinical Programs and Medical Science Director.

Dr Morris has overseen the clinical development of several global drug programs, interacting with academic groups and regulatory agencies worldwide. He brings a considerable wealth of experience to OncoTherics and will lead the company's clinical trial programme.

OncoTherics signs collaboration agreement with University of Cambridge

OncoTherics has signed a collaboration agreement with the University of Cambridge to progress a series of novel preclinical investigations using OCT1002 in Pancreatic Tumour models.

The investigations will augment OncoTherics formal preclinical studies, providing useful additional information about OCT1002 in Pancreatic Cancer.

OncoTherics signs collaboration agreement with University Health Network, Toronto

OncoTherics has signed a collaboration agreement with cancer researchers at the University Health Network, Toronto.

The investigations will augment OncoTherics formal preclinical studies, providing useful additional information about OCT1002 in Pancreatic Cancer.

Prime Minister stops by OncoTherics exhibition stand

Prime Minister, David Cameron took some time out to visit the Start Up Hub early one morning at the Conservative Party Conference.

Prime Minister David Cameron
talking with Mike Leyland

The photograph shows the Prime Minister taking a keen interest in OncoTherics and the other start-up companies presenting at the hub.

OncoTherics went on to win the best start-up award, as voted for by the delegates at the conference.